Figure 2

Clustering analysis and metabolic pathway mapping of lipid mediators in lung and plasma. (a) Clustering analysis in lung. A–D show specific clusters of lipid mediators that were altered by maoto (MT) relative to IVI. (b) Pathway mapping of lipid mediators in lung. Log₂ fold changes (log₂FC) in detected lipid mediators for IVI/NI (left column) and IVI + MT/IVI (right column) were mapped on the metabolic pathway. The percentage of increased or decreased lipid mediators for IVI/NI and IVI + MT/IVI is summarized in the table. (c) Clustering analysis in plasma. A–D show the specific cluster of lipid mediators that were altered by MT relative to IVI. (d) Pathway mapping of lipid mediators in plasma. The log₂FC in detected lipid mediators for IVI/NI (left column) and IVI + MT/IVI (right column) were mapped on the metabolic pathway. To show the related pathway of specialized pro-resolving mediators (SPMs), undetected SPMs were included on the pathway as hexagons. The percentage of increased or decreased lipid mediators for IVI/NI and IVI + MT/IVI is summarized in the table. For clustering analysis, the data were normalized and standardized by autoscale for metabolites. Euclidean distance was used for the distance measure, and Ward’s method was used for the clustering algorithm. *P < 0.05, **P < 0.01 versus IVI. ^##P < 0.01 versus NI. *P < 0.05, **P < 0.01 versus IVI. ^#P < 0.05, ^##P < 0.01 versus NI.